Bringing the Oncology Community Together

Dr. Landgren on the Standard of Care in Multiple Myeloma

Ola Landgren, MD, PhD
Published Online: Monday, April 29, 2013
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.

The standard of care in the U.S., Landgren says, includes a combination of two to three drugs administered in four cycles. Then, stem cells are collected and delivered with high-dose melphalan. Landgren says some patients are wondering if a transplant is needed, which is being examined in clinical trials.

New drugs take patients into a deeper response than ever before, Landren says. However, older patients are not candidates for procedures that include transplants, as they cannot handle the toxicities. The standard of care in this population is two to three drug cycles repeated over time followed by a more chronic treatment approach.


Related Articles
Anderson on Recent Advances in Multiple Myeloma Drugs
Pomalidomide (Pomalyst) rode impressive trial results to accelerated FDA approval this year, and Kenneth Anderson thinks it will prove a valuable new tool in the fight against multiple myeloma
B-Cell Malignancies: Transforming Expectations and Outcomes
With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.
Stemline Therapeutics Targets Capacity of Tumors to Adapt and Proliferate
The investigational cancer medications being developed by Stemline Therapeutics attack only a tiny percentage of all tumor cells. But those few cells—the stem cells that resist most treatment and drive tumor growth—may just be the most important ones.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.